Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension
Status:
Terminated
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the efficacy and safety of cobiprostone (at
two dose levels) as compared to placebo for lowering portal hypertension.
Phase:
Phase 2
Details
Lead Sponsor:
Sucampo Pharma Americas, LLC Sucampo Pharmaceuticals, Inc.